Search

USPTO Patent Application: Methods for Increasing Hematopoietic Stem Cells

The USPTO has published a patent application from Imago Biosciences, Inc. detailing methods for increasing hematopoietic stem cells and treating bone marrow failure using an LSD1 inhibitor. The application was filed on December 15, 2023, and published as US20260083729A1.

Reduced Dosing Regimens for Glaucoma Treatment Methods

The USPTO has published a patent application (US20260083746A1) detailing methods for treating open-angle glaucoma by transitioning patients to a once-daily dosing regimen. The proposed treatment involves a pharmaceutical composition containing timolol, brimonidine, dorzolamide, and bimatoprost.

USPTO Patent Application for Visual Pathway Strengthening Methods

The USPTO has published a new patent application (US20260083744A1) for methods of treating visual impairment by strengthening visual pathways. The application was filed on September 26, 2025, by inventors Ming-Fai Fong and Robert D. Lamprecht.

USPTO Patent Application: Compounds for Treating Parasitic Protozoa Infections

The USPTO has published a new patent application (US20260083728A1) detailing compounds for treating infections caused by parasitic protozoa, specifically Leishmania or Trypanosoma. The application was filed on September 18, 2023, by inventors from Karl WERBOVETZ et al.

USPTO Publishes Antiseptic Wipes Patent Application

The USPTO published a patent application for antiseptic wipes on March 26, 2026. The application details a cleansing composition including an antiseptic, humectant, emollient, surfactant, and monohydric alcohol, designed for use on a cloth. The invention also covers methods of preparing and packaging the wipes.

USPTO Patent Application: Nucleoside Derivative for Inflammation Treatment

The USPTO has published a patent application (US20260083743A1) detailing a nucleoside derivative for preventing and treating inflammation. The application, filed by WEST CHINA HOSPITAL OF SICHUAN UNIVERSITY, claims the derivative offers better efficacy and fewer side effects than existing treatments like indometacin.

Patent Application for Cancer Treatment with Azenosertib and HRD Biomarker

The USPTO has published a patent application (US20260083742A1) detailing methods for treating cancer by administering azenosertib to subjects selected based on homologous recombination repair deficiency (HRD). The application was filed on December 1, 2025.

Sotorasib Dosing Regimen Patent Application

The USPTO has received a patent application (US20260083741A1) for a sotorasib dosing regimen. The application, filed by Brett E. Houk and Panli Cardona, details methods for administering sotorasib to patients, particularly those with KRAS G12C-mutated cancer who also require treatment with a BCRP substrate like rosuvastatin.

USPTO Patent Application: Dental Composition Production Method

The USPTO has published a patent application (US20260083644A1) detailing a method for producing dental polymerizable compositions or intermediates with improved storage stability. The method involves specific steps for disposing and operating a composition within a container to achieve high yield and stability.

USPTO Patent Application: Dietary Compositions for Health and Diabetes Treatment

The USPTO has published a patent application (US20260083739A1) for dietary compositions containing minerals and vitamins, intended for various health benefits including diabetes treatment, improved athletic performance, and immune support. The application was filed on December 2, 2025.

USPTO Patent Application: Modified Release Minoxidil for Hair Loss

The USPTO has published a patent application (US20260083738A1) detailing modified release minoxidil oral formulations for treating hair loss. The application, filed by Reid Waldman, describes compositions including minoxidil alone or with other active agents, and methods of treatment. This represents a new patent filing for a potential pharmaceutical product.

USPTO Patent Application: Method for Coloring Dental Ceramic

The USPTO has published a patent application detailing a method for coloring dental ceramic using a solution containing specific metal ions. The application, filed by inventors from Japan, describes a process involving contacting the dental ceramic with a coloring liquid where the difference between standard oxidation-reduction potentials of at least two metal ions is between 0.5 and 4.0.

USPTO Patent Application: Dental Composition with Stable Paste Properties

The USPTO has published a new patent application detailing a dental composition designed for stable paste properties. The invention focuses on a specific filler composition and its surface treatment to improve long-term storage stability for dental materials.

USPTO Patent Application: Modified Release Minoxidil Formulations

The USPTO has published a patent application (US20260083737A1) detailing modified release minoxidil oral formulations and methods for treating hair loss. The application describes pharmaceutical compositions containing minoxidil or its salts, potentially with other active agents, and includes methods for their administration and related kits.

USPTO Patent Application: GOAT Inhibitors for Substance Use Disorder

The USPTO has published a patent application (US20260083736A1) for ghrelin O-acyl transferase (GOAT) inhibitors intended for the treatment of substance use disorder, particularly in patients with high impulsivity. The application details compounds of general formula I and their use in treating opioid or stimulant use disorders.

USPTO Patent Application for ABHD6 Antagonist Drug

The USPTO has published a patent application filed by ONO Pharmaceutical Co., Ltd. for a novel ABHD6 antagonist drug. The application details a compound with potential therapeutic applications for diseases associated with ABHD6 activity.

Collagenase Compositions for Orthodontic Procedures Patent Application

The USPTO has published a patent application detailing compositions comprising collagenase and their uses in orthodontic procedures. The application, filed by inventors from Israel, describes potential uses for recombinant collagenase and modified forms thereof in dental treatments.

DEA: Mississippi Meth Dealer Sentenced to 10 Years

The DEA announced the sentencing of Anthony Russell, a Mississippi meth dealer, to 10 years in prison. This action is highlighted as a victory for public safety and the agency's mission to combat drug trafficking, particularly fentanyl.

MHRA and HSA Collaborate on Healthcare Regulatory Innovation

The MHRA and Singapore's HSA have refreshed a Memorandum of Understanding to collaborate on healthcare regulatory innovation, focusing on emerging technologies like AI and advanced therapies. This partnership aims to accelerate patient access to innovative treatments while maintaining safety and trust through initiatives like work-sharing and a new Regulatory Innovation Corridor pilot.

Vesomni Tablets Defect Notification - Incorrect Barcode

The MHRA issued a Class 4 Medicines Defect Notification regarding Quadrant Pharmaceuticals Limited's Vesomni 6 mg/0.4 mg modified release tablets. The parallel imported packs have an incorrect barcode/GTIN on the carton, but the product quality is unaffected. No recall is issued, and patients do not need to take action.

Apixaban Tablets Defect Notification - MHRA

The MHRA has issued a defect notification for Sandoz Limited's Apixaban 2.5mg and 5mg tablets. Certain batches have been distributed with Patient Information Leaflets that lack up-to-date information regarding paediatric indications and post-catheter removal guidance. Affected batches will continue to be distributed without repackaging.

USPTO Patent Application for Anti-PD-1 Antibody-IL-2 Immunoconjugate Formulations

The USPTO has published a new patent application (US20260083857A1) for anti-PD-1 antibody-IL-2 immunoconjugate formulations. The application details stable pharmaceutical formulations comprising anti-human PD-1 antibody-modified human interleukin-2 immunoconjugates.

Bispecific Molecule Stabilizing Composition Patent Application

The USPTO has published a patent application (US20260083841A1) for a pharmaceutical composition designed to stabilize bispecific antigen-binding molecules at increased concentrations. The composition includes buffer agents, saccharides, and specific stabilizing agents like EDTA or citric acid.

USPTO Patent Application: NEO-201 Antibody for Suppressing Myeloid Derived Suppressor Cells

The USPTO has published a patent application (US20260083840A1) detailing methods for ablating myeloid derived suppressor cells using the NEO-201 antibody. The application describes the antibody's specific binding to certain O-glycans and its potential use in treating cancers and infectious diseases by suppressing gMDSCs.

USPTO Patent Application: Treating NSCLC with Dostarlimab or Biosimilar

The USPTO has published a patent application detailing a method for treating non-small cell lung cancer (NSCLC) using dostarlimab or a biosimilar. The application outlines a treatment approach for patients previously treated with an immune checkpoint inhibitor.

USPTO Patent Application: Modified Coronavirus Spike Antigen Protein

The USPTO has published a patent application (US20260083836A1) for a modified coronavirus spike antigen protein. The application describes a protein designed to suppress cell membrane fusion ability and improve safety by modifying cleavage sites, aiming to enhance vaccine efficacy and antibody production.

USPTO Patent Application: Phage T4 Nanoparticle Vaccine Platform

The USPTO has published a patent application (US20260083835A1) detailing a modular bacteriophage T4 nanoparticle vaccine platform. This platform is designed for the rapid development of dual COVID-19 and flu mucosal vaccines, administered intranasally without an adjuvant.

USPTO Patent Application for Immunoconjugates

The USPTO has published a new patent application, US20260083855A1, filed by Hoffmann-La Roche Inc. The application relates to immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. This filing is part of the standard patent application process.

USPTO Patent Application: Antibody Conjugates with Bis-MSPT Linker

The USPTO has published a new patent application (US20260083854A1) detailing antibody conjugates that utilize a bis-MSPT linker. The application, filed by inventors Riazul Alam, Guillermo S. Cortez, and Yan Wang, describes pharmaceutical compositions and methods related to these conjugates.

USPTO Patent Application: CD70 Antibody Drug Conjugates

The USPTO has published a new patent application (US20260083853A1) detailing CD70 antibody drug conjugates for treating cancer and autoimmune diseases. The application was filed on October 25, 2023, by inventors Xiao Shang and others.

USPTO Patent Application for Peptoid Nucleic Acid Delivery

The USPTO has published a patent application (US20260083769A1) detailing novel hydroxyalkyl-capped cationic peptoids for nucleic acid delivery. The application, filed by inventors from various institutions, describes compositions and methods for delivering polyanionic compounds to cells and eliciting immune responses.

USPTO Patent Application: Antibody Drug Conjugate Comprising NMT Inhibitor

The USPTO has published a new patent application (US20260083858A1) related to antibody drug conjugates (ADCs) that comprise an NMT inhibitor conjugated to an antibody via a linker. The application details the inventors and abstract of the invention.

USPTO Patent Application: IL-17 Antibody Compositions

The USPTO has published a patent application (US20260083842A1) detailing pharmaceutical products and stable liquid compositions of IL-17 antibodies, such as secukinumab. The application covers methods of making these compositions and their use in treating IL-17-mediated disorders, including autoimmune conditions like psoriasis and rheumatoid arthritis.

USPTO Patent Application for CsgA-Derived Nanostructures for Antigen Delivery

The USPTO has published a patent application (US20260083834A1) for CsgA-derived nanostructures designed for antigen delivery. The application details self-assembling polypeptides conjugated to immunogens that form nanofilaments to stimulate immune responses, potentially for vaccines against various conditions.

USPTO Patent Application: Engineered Probiotics Expressing Anti-Inflammatory Molecules

The USPTO has published a patent application (US20260083783A1) from the University of Cincinnati for engineered probiotics that express anti-inflammatory molecules. The application details a genetically modified E. coli bacterium designed to produce a microbial anti-inflammatory molecule (MAM) protein.

USPTO Patent Application for Generating CD4 T Cells

The USPTO has published a patent application (US20260083778A1) for methods of generating CD4 T cells from progenitor cells. The application, assigned to Boston Medical Center Corporation, describes a specific differentiation process for therapeutic use.

USPTO Patent Application: CARs for Hidradenitis Suppurativa Treatment

The USPTO has published a patent application (US20260083777A1) filed by Sonoma Biotherapeutics, Inc. The application describes chimeric antigen receptors (CARs) designed to target citrullinated polypeptides for the treatment of hidradenitis suppurativa.

USPTO Patent Application: Cancer Treatment with Anti-CD20 Antibody and Acylfulvenes

The USPTO has published a patent application (US20260083691A1) filed by Lantern Pharma Inc. The application describes a method for treating cancer by combining an anti-CD20 antibody with acylfulvenes. This patent application is related to novel therapeutic combinations for B-cell cancers.

USPTO Patent Application: Thiazolidine Linkers for Protein-Drug Conjugates

The USPTO has published a new patent application (US20260083856A1) detailing thiazolidine linkers for protein-drug conjugates and their uses in treating diseases. The application was filed on September 11, 2025, and is scheduled for publication on March 26, 2026.

USPTO Patent Application: Anti-DPP3 Antibody Formulations

The USPTO has published a patent application from 4TEEN4 Pharmaceuticals GmbH for formulations and dosage amounts for administering an anti-DPP3 antibody or fragment thereof to humans. The application, filed on August 26, 2025, details potential treatments for life-threatening circulatory failure conditions such as shock.

USPTO Patent Application: Recombinant Human Type III Collagen for Angiogenesis

The USPTO has published a patent application (US20260083883A1) detailing recombinant human type III collagen designed to promote angiogenesis. The application describes modifications to natural type III collagen to enhance its angiogenic function and adhesion properties, potentially increasing the angiogenesis rate by over 37%.

USPTO Patent Application: Compositions Targeting Endothelial Cells

The USPTO has published a patent application from Harvard College detailing novel compositions for targeting endothelial cells. These compositions, which include binders, linkers, and radioactive isotopes, are intended for selective delivery to cells and treating diseases, including cancer.

USPTO Patent Application: Sustained Transgene Expression of Modified ERT2 Peptide Fusion

The USPTO has published a patent application (US20260083859A1) detailing a novel fusion polypeptide for sustained transgene expression. The application, filed by inventors from various institutions, describes targeting constructs for inducible cell death systems using modified estrogen receptor ligand binding domains.

USPTO Patent Application for Capsid Polypeptides

The USPTO has published a new patent application (US20260083863A1) from Dyno Therapeutics, Inc. for capsid polypeptides designed for payload delivery. The application details specific polypeptide sequences and their methods of use in therapeutic applications.

Lamotrigine Salts, Co-crystals, and Compositions Patent Application

The USPTO has published a patent application (US20260083745A1) for lamotrigine oral suspension and its preparation method, filed by Azurity Pharmaceuticals Ireland Limited. The application details a formulation designed to improve the stability and redispersibility of lamotrigine suspensions.

Patent Application: 7-Cyano-8-Hydroxyquinoline Derivative Medical Use

The USPTO has published a patent application for a 7-cyano-8-hydroxyquinoline derivative, its preparation method, and its medical use in treating infectious diseases or cancer. The application details a compound with potential antibacterial, antiviral, and antitumor activity.

Iowa Board of Pharmacy Newsletter: Rule Delays, MPJE Update, New Board Members

The Iowa Board of Pharmacy announced a 70-day administrative delay for adopted rules that would have rescinded and created new chapters in the Iowa Administrative Code. Despite this delay, the Multistate Pharmacy Jurisprudence Examination (MPJE) content will reflect the new rules effective August 1, 2025, to prepare new graduates and out-of-state pharmacists for eventual implementation.

Iowa Board of Pharmacy Newsletter: Rule Review and PMP Changes

The April 2025 Pharma Phacts newsletter from the Iowa Board of Pharmacy details ongoing administrative rule reviews mandated by Executive Order 10. Two chapters have been republished under Amended Notices of Intended Action following public comment, with a comment period closing March 25, 2025. The newsletter also notes the Board of Pharmacy rules are moving to Agency ID 481 under the Department of Inspections, Appeals, and Licensing (DIAL).

Iowa Board of Pharmacy Newsletter October 2025

The Iowa Board of Pharmacy newsletter for October 2025 announces new board members and updates on expanded authority for statewide protocol development. It also details changes to business license application processes allowing retention of existing license numbers and notes that Long-Term Care Facilities and Assisted Living Facilities no longer require CSA registration.

Iowa Board of Pharmacy Adopts UMPJE Exam, Updates PMP Access

The Iowa Board of Pharmacy announced the adoption of the Uniform Multistate Pharmacy Jurisprudence Exam (UMPJE) effective April 1, 2026, and updated access policies for its Prescription Management Program (PMP). Pharmacist access to the Rx Management tool is now restricted to those with a DEA registration number, and data submissions missing a prescriber's DEA number will be flagged as errors.